Charcot-Marie-Tooth Disease Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceSupports muscle function and bone health; CMT patients at risk for osteoporosis and falls
Supporting Studies (1)
Supports mitochondrial function and nerve energy metabolism; studied in various neuropathies
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsSupports nerve function and energy metabolism; studied for peripheral neuropathies
Supporting Studies (1)
Antioxidant with neuroprotective properties; supports nerve function
Supporting Studies (1)
Support nerve health and myelin; B1, B6, B12 especially important for peripheral nerves
Supporting Studies (1)
Anti-inflammatory; supports nerve cell membrane health
Supporting Studies (1)
Supports bone health; CMT patients at increased fall and fracture risk
Supporting Studies (1)
Supports muscle function and nerve signaling; may help with cramps
Supporting Studies (1)
Anti-inflammatory and neuroprotective; studied in animal models of CMT
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that affect the peripheral nerves - the nerves outside your brain and spinal cord. CMT causes progressive muscle weakness and atrophy, typically starting in the feet and legs and sometimes progressing to the hands. It also causes sensory changes (numbness, tingling) and often high-arched feet and hammertoes.
CMT TYPES:
THERE IS NO CURE FOR CMT, but management includes:
CAUTION - MEDICATIONS TO AVOID:
Certain medications can worsen CMT symptoms, including vincristine (chemotherapy), high-dose vitamin B6, and certain antibiotics. Always inform healthcare providers about your CMT.
* Vitamin D and Calcium support bone health, which is especially important given the increased fall risk with CMT.
* Acetyl-L-Carnitine has been studied for peripheral neuropathies and may support nerve function.
* B Vitamins support nerve health, but avoid high doses of B6 (>100mg) as excess B6 can cause neuropathy.
* CoQ10 and Alpha-Lipoic Acid support cellular energy and have antioxidant properties.
Expected timeline: CMT is a slowly progressive condition. Supplements may support nerve health but will not reverse the disease. Physical therapy and orthotic devices remain the mainstays of management.
Clinical Perspective
Charcot-Marie-Tooth Disease: Most common inherited peripheral neuropathy; prevalence 1:2500. Types: CMT1 (demyelinating, 60-70% of cases; CMT1A from PMP22 duplication most common), CMT2 (axonal), CMTX (X-linked), CMT4 (autosomal recessive). Presentation: distal muscle weakness and atrophy (peroneal atrophy), sensory loss, foot deformities (pes cavus, hammertoes), steppage gait, later hand involvement. Onset typically first or second decade. Progression slow but variable.
CRITICAL: No disease-modifying treatment available. Management is supportive. Physical therapy essential. Orthotics (AFOs) for foot drop. Surgery for severe deformities. Pain management if neuropathic pain. AVOID neurotoxic medications (vincristine, high-dose B6, cisplatin, metronidazole, nitrofurantoin - see CMT foundation list). Supplements are SUPPORTIVE; do not alter disease course.
* Vitamin D (B-grade): Muscle; bone health (fall risk increased). Systematic review: (PMID: 28828084). 2000-4000 IU daily.
* Coenzyme Q10 (C-grade): Mitochondrial support. Review: (PMID: 26597398). 200-400mg daily.
* Acetyl-L-Carnitine (B-grade): Nerve metabolism. Meta-analysis: peripheral neuropathy (PMID: 25572038). 1000-2000mg daily.
* Alpha-Lipoic Acid (C-grade): Neuroprotection. Review: (PMID: 27840029). 600mg daily.
* B-Complex (B-grade): Nerve support. Systematic review: (PMID: 28660890). Daily. AVOID >100mg B6 (causes neuropathy).
* Omega-3 (C-grade): Nerve membranes. Review: (PMID: 27840029). 2-3g EPA+DHA daily.
* Calcium (B-grade): Bone health. Guidelines: (PMID: 27614127). 1000-1200mg daily.
* Magnesium (C-grade): Muscle function; cramps. Review: (PMID: 28150472). 300-400mg daily.
* Curcumin (C-grade): Neuroprotection; animal data. Review: (PMID: 25282711). 500-1000mg daily.
Assessment targets: Functional assessments (CMT Neuropathy Score, 6MWT, hand function tests), nerve conduction studies (disease monitoring, not diagnostic at follow-up), quality of life, fall risk, bone density.
Protocol notes: Research trials: ongoing gene therapy and other trials - encourage patients to consider clinical trial participation (see CMTRF.org). Physical therapy: stretching, strengthening, balance training; should be regular and lifelong. AFOs: can dramatically improve gait; proper fitting essential. Footwear: extra-depth shoes, custom orthotics; avoid barefoot walking. Hand function: occupational therapy for adaptive tools if hands affected. Falls: high risk; home safety assessment; consider PT for balance training. Driving: may need hand controls if foot weakness severe; driving evaluation. Fatigue: common complaint; pacing activities; energy conservation. Pain: neuropathic pain in ~40%; gabapentin, pregabalin, duloxetine may help. High-dose vitamin C: was studied for CMT1A (theory: reduces PMP22 expression) but trials did not show benefit. PXT3003: combination therapy in trials for CMT1A. Weight management: excess weight increases burden on weakened muscles. Pregnancy: genetic counseling; CMT does not contraindicate pregnancy but may affect delivery options.